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Summary In a comparative double-blind trial involving 263 postmenopausal women with advanced breast
cancer treated with tamoxifen, the mean objective tumour response rate and duration was 32% and 15
months respectively. No significant difference was found in clinical response and adverse effects between those
randomised to 10mg and those to 20mg twice daily. Although the mean serum concentration of tamoxifen in
the 20mg bd group was significantly higher no correlation between serum level and clinical benefit was
demonstrated.
Tamoxifen (Nolvadex*) is widely used as a first line
therapy in the management of breast cancer. Early
clinical results indicated that the threshold of
consistent therapeutic activity lay between 10 and
20mg daily. Ward (1973), in a small randomised
comparison of 10mg bd and 20mg bd, reported a
greater tumour response rate at the higher dose,
although the difference was not statistically
significant. The only other direct comparison of
two dosages was a non-randomised study (Lerner et
al., 1976) in which the results were considered
inconclusive. A review of 19 major clinical trials
(Mouridsen et al., 1978) suggested that a dose of
40mg daily was associated with a higher overall
response than 20mg daily (39% versus 28%) but
this conclusion needs confirming in a prospective
randomised trial.
Recently a method for analysing concentrations
of tamoxifen in serum has become available (Adam
et al., 1980a). No correlation between serum
concentrations and clinical response was found in
39 patients but it was recommended that a further
study in a larger number of patients was required
(Patterson et al., 1980).
The purpose of this trial was to compare tumour
response rate and duration between the two most
commonly used dosage regimens of tamoxifen, viz
10mg bd and 20mgbd, and to attempt to correlate
clinical response with serum tamoxifen level in a
large number of patients.
*"Nolvadex" is a Trade Mark, the property of Imperial
Chemical Industries PLC.
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Patients and methods
The trial was carried out at two separate centres
(Cambridge and Southampton).
Postmenopausal women with primary inoperable,
locally recurrent or metastatic breast cancer with
measurable or evaluable disease were assessed.
Patients previously treated with tamoxifen and
those receiving other endocrine therapies within the
previous 6-weeks were excluded. During the trial,
concomitant anticancer medication was not
permitted, with the exception of palliative
radiotherapy for painful bone metastases, which
were then excluded as evaluable lesions.
Patients were allocated, double blind, to receive
tamoxifen either 0mg or 20mg twice daily in the
form ofmatching tablets by the hospital pharmacist
using a computer-generated randomisation code.
Because the supply of matching 20mg tablets was
limited, only 4 months' treatment was provided for
each patient. After 4 months' therapy the code for
individual patients was broken and further
tamoxifen was prescribed using conventional sales
material ("Nolvadex" 10mg).
General clinical status, side effects and soft tissue
disease were evaluated monthly for the first 4
months. Bone and lung lesions were assessed
radiologically on entry and at 3 months. Hepatic
involvement was judged clinically by measuring
liver size below the costal margin. Tumour response
to therapy was assessed according to the U.I.C.C.
criteria (Hayward et al., 1977, 1978). Briefly, the
four response categories were defined as follows:
Complete response (CR) disappearance of all
known lesions, determined by two observations not
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less than 4 weeks apart. In the case of lytic bone
metastases, these must be shown radiologically to
have calcified.
Partial response (PR) Firty percent decrease in
measurable lesions and objective improvement in
evaluable bur non-measurable lesions, determined
by two observations not less than 4 weeks apart.
No new lesions should have appeared. It is not
necessary for every lesion to have regressed to
qualify for partial response, but no lesion should
have progressed.
No change (NC) lesions unchanged (i.e. 50%
decrease or 25% increase in the size of measurable
lesions). If non-measurable but evaluable lesions
represent the bulk of disease and these clearly do
not respond even though measurable lesions have
improved, then this is considered as no change and
not partial response.
Progressive disease (PD) Twenty-five percent
increase in the size of any lesion or the appearance
of new lesions.
Patients withdrawing from the trial for any
reason during the first 4 weeks were considered to
be "treatment failures".
Initial response was assessed at 3 months and
confirmed at 4 months. Tamoxifen treatment was
continued in patients achieving CR or PR or NC
with stable/improving performance status at the
discretion of the physician. Tamoxifen was
discontinued after 3 months if patients showed PD
or NC with deteriorating performance status and
was also withdrawn at any time when rapid disease
progression or intolerable side effects occurred.
The duration of response was taken as the length
of time between the start of tamoxifen therapy and
documentation of progressive disease, the
introduction of additional or alternative anticancer
medication or the withdrawal of tamoxifen.
Tumour response data were audited by exchange
of record forms between the principal investigators
of the two centres.
The proportion of responders has been analysed
using logistic regression. The terms fitted were dose,
age, disease-free interval, presence/absence of
primary tumour and dominant site. Duration of
response has been compared between the two dose
groups using the logrank test (Peto et al., 1977).
Where possible two 10ml samples of blood were
taken from each patient at least one month apart
between the 8th and 16th week of treatment by
which time steady state kinetics were assumed to
have been reached (Patterson et al., 1980). Serum
was analysed for tamoxifen and desmethyl
metabolite concentrations using the method
described by Adam et al. (1980b). Results were not
disclosed to the clinician until the trial was
complete.
Results
Of 263 patients recruited, 26 (15 on 10mgbd; 11 on
20mgbd) were excluded from the analysis on the
grounds of protocol ineligibility or inadequacy of
data recording. A further 16 (11 on 10mgbd; 5 on
20mgbd) were withdrawn from the trial within
four weeks of starting treatment for the reasons
shown in Table I and these were classified as
treatment failures.
Distribution of the 237 assessable patients by
dose according to baseline characteristics is shown
in Table II. The two groups were well matched
except for a preponderance of bone-dominant
disease (25 versus 14) and correspondingly fewer
patients with soft tissue dominant disease (70 versus
75) in the higher dose group. However the logistic
regression method of analysis used takes into
account any imbalance in prognostic variables
(Armitage & Gehan, 1974). Most patients (96%)
had not received any previous systemic additive
treatment for their disease.
With 237 evaluable patients there is an 80%
chance of obtaining a statistically significant result
at the 5% level (two-tailed) if the true difference in
response rates was at least 18% (30-48%).
Table I Reasons for withdrawal from trial
within 4 weeks
No. ofpatients
JOmgbd 20mgbd
Death 4 1
Withdrawn due to side
effects 1 1
Defaulted 4 3
Rapid deterioration 1
Other 1
11 5
Tumour response rates
Objective tumour response rates (CR+PR) are
shown in Table III. Thirty-four percent (39/116) of
patients in the 10mgbd group achieved more than
50% tumour regression compared with 31%
(37/121) in the 20mgbd group. Inclusion of
patients achieving disease stabilisation (NC) gives
response rates of 50% (58/116) and 57% (69/121)
respectively. None of these differences is statistically
significant.TAMOXIFEN DOSAGE IN BREAST CANCER 201
Table II Patient demography
Dose oftamoxifen
J0mgbd 20mgbd
No. of patients
Age (yr)
Mean
Range
Disease free interval:
yr
1-5 yrs
>5 yrs
Not documented
Previous treatment:
None
Surgery
Radiotherapy
Other
Primary tumour:
Present
Absent
Not documented
Dominant site:
Soft tissue
Bone
Visceral
Not documented
116 121
69.3 67.4
45-91 38-89
62
38
15
1
41
57
56
4
54
61
1
75
14
26
1
63
40
17
1
Table IV Tumour response to tamoxifen by
dominant site regardless of dose
Dominant site
Tumour
response Soft tissue Bone Visceral
CR 20 1 2
PR 38 8 7
NC 34 9 8
PD 50 18 26
Failures 3 3 8
CR+PR 58/145 9/39 9/51
(40.0%) (23.1%) (17.6%)
42
69
45
S
50
70
1
70
25
25
1
Table V Tumour response to tamoxifen
by primary tumour regardless ofdose
Primary tumour
Tumour
response Present Absent
CR 2 21
PR 24 29
NC 28 23
PD 44 50
Failures 6 8
CR+PR 26/104 50/131
(25.0%) (38.2%)
Table III Tumour response to tamoxifen by dose level
Tamoxifen
Tumour response JOmgbd 20mgbd
CR 14 9
PR 25 28
NC 19 32
PD 47 47
Failure 11 5
CR+PR 39/116 (33.6%) 37/121 (30.6%)
CR+PR+NC 58/116 (50.0%) 69/121 (57.0%)
With respect to prognostic variables, a significant
correlation between both the dominant site of
disease and presence/absence of primary tumour
and tumour response to therapy was found. In the
case of dominant site (Table IV), the response rate
was significantly higher for soft tissue dominant
disease than either bone dominant (P=0.037) or
visceral dominant (P=0.003) disease. in the case of
presence/absence of primary tumour (Table V),
those patients with a primary tumour irrespective of
other lesions showed a statistically significantly
lower (P=0.035) response rate than those without a
primary tumour.
Response with respect to age and disease free
interval (DFI) are shown in Tables VI and VII. The
differences in response rates between the various
strata did not achieve statistical significance,
although some trend towards an increasing
response rate with age up to 80 years and length of
DFI is evident.
Table VI Tumour response to tamoxifen by age
regardless ofdose
Age range (years)
Tumour
response <60 60-69 70-79 >80
CR 4 5 11 3
PR 8 18 19 8
NC 8 15 14 14
PD 25 35 27 7
Failures 6 2 3 2
CR+PR 12/51 23/75 30/74 11/34
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Table VII Tumour response by disease
free interval regardless ofdose
Diseasefree interval (y)
Tumour
response <Jy 1-Sy >5y
CR 4 13 6
PR 30 17 6
NC 33 10 8
PD 52 32 10
Failures 6 6 2
CR+PR 34/125 30/78 12/32
(27.2%) (38.5%) (37.5%)
Duration ofresponse
The median durations of objective response for the
l0mgbd and 20mgbd groups were 18 and 12
months respectively. This difference is not
statistically significant (P<0.10). At the time when
data was analysed 20 patients (51%) in the
10mgbd and 14 (38%) in the 20mgbd group were
still in remission.
Both groups of patients were followed up
identically, to either the date of withdrawal from
the trial or if response was continuing, to the date
of analysis. In both groups, the median duration of
follow-up was 4 months.
Improvement ofresponse category after the trial
Although tumour response to treatment was only
assessed double-blind for four months and response
rates quoted above refer to the situation during
that period, 10 patients subsequently showed
improvement in response category and the majority
of these eventually achieved complete remission of
their disease (Table VIII). One patient with
Table VIII Improval of tumour response category
after the initial four month treatment period
Initial
classification Best
Dosage group (4 month) response
PDa - CR
NC - PR
PR - CR
10mgbd PR - CR
PD - PR
PR - CR
PR - CR
NC - PR
20mgbd NC - CR
PR - CR
aDose changed to 20mgbd.
progressive disease after 4 months on the lower
dose became a complete responder when the dose
was increased to 20mgbd.
Adverse reactions
A total of 31 adverse effects were reported by 24
(9%) of the patients entered but there was no
consistent indication that these were dose-related
(Table IX). Three patients (1%) were withdrawn
due to treatment intolerance: paroxysmal nocturnal
dyspnoea (1 patient at 20mgbd), vaginal discharge
(1 patient at 20mgbd), oedema (1 patient at
10mgbd). Against the spontaneous background
incidence of symptoms in women with advanced
malignancy and in the absence of a control group
however, it is impossible to ascertain what
proportion of these symptoms was definitely drug-
related.
Table IX Side effects associated with tamoxifen
therapy
Number ofpatients
Side effect 10mgbd 20mgbd
Nausea 3 3
Vomiting 1 0
Hot flushes 1 1
Vaginal discharge 1 2
Vaginal bleeding 0 1
Pruritis 0 1
Cardiac failure 2 2
Dyspnoea 1 0
Anorexia 0 1
Abdominal pain 0 1
Constipation/diarrhoea 2 0
Dysphagia 0 1
Tiredness 0 4
Depression 0 1
Vertigo 1 0
Bone pain 0 1
Total 12 19
Serum tamoxifen analysis
Serum samples for drug analysis were obtained
from 152 subjects (64% of evaluable cases). In 59
patients only a single sample was available. In the
remaining 93 cases the mean value of the two
determinations was used. Concentrations of
tamoxifen and desmethyltamoxifen were within
20% of each other in 60 and 58 instances
respectively and in 45 instances for both
compounds. Hence in this subgroup steady state
kinetics were unequivocally demonstrated but
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concentrations with clinical results were
unsuccessful. The ratio of metabolite to parent
compound was reasonably constant thus allowing
the ratio to be used as an indication of patient
compliance; poor compliance would result in higher
metabolite concentrations because of the longer half
life of the latter compound leading to an increased
metabolite/parent compound ratio.
Table X shows the results of analysis of variance
of serum concentrations allowing for dose and
response (CR+PR) and the interaction between
these parameters. There were no significant
differences between responders and non-responders
either within a dose group or on combining dose
groups. The mean serum concentrations of
159ngml-' and 273ngml-1 for 10 and 20mgbd
respectively were markedly different (P<0.0001).
Figure 1 shows the scattergram of serum
concentrations of tamoxifen in the two dose
groups.
In the group in which steady state kinetics were
proven, the mean ratio of metabolite to unchanged
drug concentration was 1.79+0.01 (n=25) for the
10mgbd group and 1.87+0.08 (n=20) for the
20mgbd dose group. These were not significantly
different. This suggests there was no difference in
compliance between the two groups ofpatients.
Table X Serum tamoxifen concentrations for all
patients
Dose oftamoxifen
Response 1Omgbd 20mgbd OveralP
Responders Mean 158.6 289.6 224.la
s.e. 11.1 20.2 11.4
n 36 28 64
Non-responders Mean 160.0 256.8 208.4a
s.e. 11.3 15.7 9.6
n 41 47 88
Overallb Mean 159.3a 273.2a
s.e. 10.3 10.8
n 77 75
aThese means have been adjusted to allow for the
unequal numbers in the cells.
bOverall difference between dose levels significant
(P<0.0001).
cOverall difference between responders and non-
responders not significant (P> 0.05).
Discussion
The results of this trial involving 237 evaluable
postmenopausal patients with advanced breast
cancer have failed to detect a significant therapeutic
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Figure 1
advantage for a tamoxifen dose of 20mgbd
compared with 10mgbd. In a previous smaller
comparison between 20 and 40mg daily (Ortiz de
Taranco et al., 1979), the objective response rates
were also not significantly different. However,
consideration of the NC group brought the total
response rates (CR+PR+NC) to 51% for 20mg
daily and 79% for 40mg daily thus demonstrating
a statistically significant advantage for the higher
dose. The corresponding overall response rates in
our trial were 50% and 57% which concurs with
_
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this previous finding although our beneficial trend
was not marked. Inclusion of patients obtaining
disease stabilisation should be considered to be
worthwhile, however, because survival in this group
of patients may be as long as in those experiencing
partial tumour remissions (Henningsen & Amerger,
1977; Cavalli et al., 1983).
Premenopausal patients were excluded from this
trial. The efficacy of doses as low as 10mgbd in
such patients has been questioned on the grounds
that this dose may not completely antagonise their
high endogenous levels of oestrogens (Manni &
Pearson, 1980; Santen et al., 1981). The results of
this study should not therefore be extrapolated to
the premenopausal age group. This study also does
not exclude the possibility of a response to higher
doses after failure at lower doses; 23% (7/30) of
patients with documented progressive disease on
20mg tamoxifen daily have previously been
reported to have achieved disease stabilisation for
up to 15 months when the dose was increased to
40mg daily although no objective responses were
observed (Stewart et al., 1982). We have now
described one complete remission in a patient given
20mgbd when previously unresponsive to 10mgbd.
However, one patient with progressive disease
developed a partial response with no change in
therapy.
It is interesting that the overall response rate,
side effect profile and prognostic trends emerging
from the trial (i.e. correlation of response to
dominant site, age, disease free interval etc.) are
similar to those reported in reviews of published
clinical trials (Mouridsen et al., 1978; Patterson,
1981) suggesting that our patient sample was
representative of the population normally treated.
The lower response rate in patients with primary
tumours, irrespective of dose, is probably a
function of the size of the lesion (5cm by definition
of "inoperable"), making the criterion for partial
response (more than 50% decrease in the product
of perpendicular diameters) more difficult to
achieve because of the increased tumour burden.
This is supported by the fact that addition of the
NC category obliterates the significant difference in
response rates for patients with and without
primary tumour (52% and 56% respectively).
Some patients clearly required longer than 4
months to achieve an optimal therapeutic response.
Indeed, two patients who had actually been
classified as having progressive disease at 4 months
subsequently responded (one CR and one PR). This
observation has previously been reported by Glick
et al. (1980) who recommended that tamoxifen
should not be discontinued unless progressive
disease is documented or significant symptomatic
deterioration occurs.
In both groups of patients the serum
concentration of tamoxifen varied widely. This
probably results from a combination of a
population spread in half-life and presumed
invariable, but unknown degrees of incomplete
compliance. However, the spread was similar in
both groups and the mean serum concentration in
the 20mgbd group was approximately double that
for the lower dose. Despite this difference in serum
concentrations, there was no identifiable difference
in clinical response. One possible explanation might
be that the circulating tamoxifen levels may not
necessarily reflect cytoplasmic concentrations in
target cells, particularly in tumours with abnormal
vasculature. Furthermore, oestrogen receptor status,
which may be an important factor in determining
response to endocrine therapy, was not measured in
patients in this study and hence receptor imbalance
between the patient groups cannot be excluded.
In conclusion, tamoxifen has been confirmed to
be a safe and effective therapy for postmenopausal
women with advanced breast cancer, the mean
objective response rate being 32% with less than
1% of patients stopping treatment because of side
effects. However, no statistically significant
advantage for 40mg daily over 20mg daily has
been found, neither was there any evidence of a
correlation between tumour response and serum
tamoxifen level.
We are grateful to H.K. Adam and J.V. Kemp for
analysing serum samples and S.H. Ellis for performing the
statistical analyses. The advice of L. Battersby and H. de
Haan was much appreciated. We are also grateful to Mrs
P.C. Williams and Mrs I.K. Bell for supervising the
accurate collection ofclinical data.
References
ADAM, H.K., GAY, M.A. & MOORE, R.H. (1980a).
Measurement of Tamoxifen in serum by thin-layer
densitometry. J. Endocrinol., 84, 35.
ADAM, H.K., PATTERSON, J.S. & KEMP, J.V. (1980b).
Studies on the metabolism and pharmacokinetics of
tamoxifen in normal volunteers. Cancer Treat. Rep.,
64, 761.
CAVALLI, F., BEER, M., MARTZ, G. & 5 others. (1983).
Concurrent or sequential use of cytotoxic
chemotherapy and hormone treatment in advanced
breast cancer. Br. Med. J., 286, 5.TAMOXIFEN DOSAGE IN BREAST CANCER 205
GLICK, J.H., CREECH, R.H., TORRI, S. & HOLROYDE, C.
(1980). Tamoxifen plus sequential CMF chemotherapy
versus tamoxifen alone in postmenopausal patients
with advanced breast cancer: a randomised trial.
Cancer, 45, 735.
HAYWARD, J.L., CARBONE, P.P., HEUSON, J.C. & 3
others. (1977). Assessment of response to therapy in
advanced breast cancer. Cancer 39, 1289.
HAYWARD, J.L., RUBENS, R.D., CARBONE, P.P. & 4
others. (1978). Assessment of response to therapy in
advanced breast cancer. Eur. J. Cancer, 14, 1291.
HENNINGSEN, B. & AMBERGER, H. (1977).
Antiostrogene therapie des metastasierenden
mammakarzinoms. Deut. Med. Wochenschr., 102, 713.
LERNER, H.J., BAND, P.R., ISRAEL, L. & LEUNG, B.S.
(1976). Phase II study of tamoxifen. Report of 74
patients with stage IV breast cancer. Cancer Treat.
Rep., 60, 1431.
MANNI, A. & PEARSON, O.H. (1980). Antioestrogen-
induced remissions in premenopausal women with
stage IV breast cancer: Effects on ovarian function.
Cancer Treatl Rep., 64, 779.
MOURIDSEN, H., PALSHOF, T., PATTERSON, J. &
BATTERSBY, L. (1978). Tamoxifen in advanced breast
cancer. Cancer Treat. Rev., 5, 131.
ORTIZ DE TARANCO, A.V., DONNAY CANDIL, 0. &
BAENA HERRERA, L. (1979). Treatment of Stage IV
breast cancer with antioestrogens (nolvadex) in 78
postmenopausal patients. Oncologia 80, 8.
PATTERSON, J.S. (1981). "Nolvadex" (tamoxifen) as an
anti-cancer agent in humans. In: Non-steroidal
Antioestrogens. (Eds. Sutherland & Jordan), Sydney:
Academic Press, p. 453.
PATTERSON, J.S., SETTATREE, R.S., ADAM, H.K. & KEMP,
J.V. (1980). Serum concentration of tamoxifen and
major metabolite during long-term nolvadex therapy
correlated with clinical response. In: Breast Cancer,
Experimental and Clinical Aspects. (Eds. Mouridsen &
Palshof) Where: Pergamon Press, p. 89.
PETO, R., PIKE, M.C., ARMITAGE, P. & 7 others. (1977).
Design and analysis of randomised clinical trials
requiring prolonged observation of each patient. Br. J.
Cancer, 35, 1.
SANTEN, R.J., VELDHUIS, J.D., HARVEY, H.A. & LIPTON,
A. (1981). Chemotherapy and tamoxifen for breast
cancer. New Engl. J. Med., 305, 1014.
STEWART, J.F., MINTON, M.J. & RUBENS, R.D. (1982).
Trial of tamoxifen at a dose of 40mg daily after
disease progression during tamoxifen therapy at a dose
of20mg daily. Cancer Treat. Rep., 66, 1445.
WARD, H.W.C. (1973). Anti-oestrogenic therapy for breast
cancer: A trial of tamoxifen at two dose levels. Br.
Med. J., i, 13.